Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
11
LENZ Quote, Financials, Valuation and Earnings
Last price:
$17.14
Seasonality move
:
-5.91%
Day range:
$16.26 - $17.46
52-week range:
$15.70 - $50.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
26.94x
P/B ratio:
2.73x
Volume:
810.9K
Avg. volume:
1.2M
1-year change:
-46.04%
Market cap:
$528.5M
Revenue:
--
EPS (TTM):
-$2.11
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LENZ
LENZ Therapeutics, Inc.
|
$4.6M | -$0.69 | -7.14% | -109.39% | $53.71 |
|
CDT
CDT Equity, Inc.
|
-- | -- | -- | -- | -- |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
-- | -$0.69 | -100% | -499.94% | $46.56 |
|
ORKA
Oruka Therapeutics, Inc.
|
-- | -$0.52 | -- | -1.78% | $49.45 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LENZ
LENZ Therapeutics, Inc.
|
$16.89 | $53.71 | $528.5M | -- | $1.03 | 0% | 26.94x |
|
CDT
CDT Equity, Inc.
|
$1.59 | -- | $2.6M | -- | $0.00 | 0% | -- |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
MAZE
Maze Therapeutics, Inc.
|
$42.30 | $46.56 | $2B | -- | $0.00 | 0% | 501.13x |
|
ORKA
Oruka Therapeutics, Inc.
|
$31.71 | $49.45 | $1.5B | -- | $19.36 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LENZ
LENZ Therapeutics, Inc.
|
0.49% | -0.080 | 0.07% | 12.39x |
|
CDT
CDT Equity, Inc.
|
30.47% | -0.945 | 27% | 1.13x |
|
LIMN
Liminatus Pharma
|
-- | 0.000 | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
5.99% | 0.000 | 1.94% | 17.36x |
|
ORKA
Oruka Therapeutics, Inc.
|
0.39% | 1.816 | 0.2% | 16.65x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LENZ
LENZ Therapeutics, Inc.
|
$12.4M | -$18.9M | -28.93% | -29.1% | -151.1% | -$9M |
|
CDT
CDT Equity, Inc.
|
-$885K | -$7M | -898.82% | -- | -- | -$4.4M |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
-$571K | -$33M | -30.65% | -35.16% | -- | -$24.7M |
|
ORKA
Oruka Therapeutics, Inc.
|
-$20K | -$34.1M | -25.67% | -25.76% | -- | -$21.7M |
LENZ Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns LENZ or CDT?
CDT Equity, Inc. has a net margin of -133.6% compared to LENZ Therapeutics, Inc.'s net margin of --. LENZ Therapeutics, Inc.'s return on equity of -29.1% beat CDT Equity, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LENZLENZ Therapeutics, Inc.99% -$0.59 $194.9M CDTCDT Equity, Inc.-- -$13.16 $6.2M -
What do Analysts Say About LENZ or CDT?
LENZ Therapeutics, Inc. has a consensus price target of $53.71, signalling upside risk potential of 218.02%. On the other hand CDT Equity, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that LENZ Therapeutics, Inc. has higher upside potential than CDT Equity, Inc., analysts believe LENZ Therapeutics, Inc. is more attractive than CDT Equity, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LENZLENZ Therapeutics, Inc.6 0 0 CDTCDT Equity, Inc.0 0 0 -
Is LENZ or CDT More Risky?
LENZ Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CDT Equity, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LENZ or CDT?
LENZ Therapeutics, Inc. has a quarterly dividend of $1.03 per share corresponding to a yield of 0%. CDT Equity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENZ Therapeutics, Inc. pays -- of its earnings as a dividend. CDT Equity, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LENZ or CDT?
LENZ Therapeutics, Inc. quarterly revenues are $12.5M, which are larger than CDT Equity, Inc. quarterly revenues of --. LENZ Therapeutics, Inc.'s net income of -$16.7M is lower than CDT Equity, Inc.'s net income of -$7.1M. Notably, LENZ Therapeutics, Inc.'s price-to-earnings ratio is -- while CDT Equity, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENZ Therapeutics, Inc. is 26.94x versus -- for CDT Equity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LENZLENZ Therapeutics, Inc.26.94x -- $12.5M -$16.7M CDTCDT Equity, Inc.-- -- -- -$7.1M
-
Which has Higher Returns LENZ or LIMN?
Liminatus Pharma has a net margin of -133.6% compared to LENZ Therapeutics, Inc.'s net margin of --. LENZ Therapeutics, Inc.'s return on equity of -29.1% beat Liminatus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LENZLENZ Therapeutics, Inc.99% -$0.59 $194.9M LIMNLiminatus Pharma-- -- -- -
What do Analysts Say About LENZ or LIMN?
LENZ Therapeutics, Inc. has a consensus price target of $53.71, signalling upside risk potential of 218.02%. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that LENZ Therapeutics, Inc. has higher upside potential than Liminatus Pharma, analysts believe LENZ Therapeutics, Inc. is more attractive than Liminatus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings LENZLENZ Therapeutics, Inc.6 0 0 LIMNLiminatus Pharma0 0 0 -
Is LENZ or LIMN More Risky?
LENZ Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LENZ or LIMN?
LENZ Therapeutics, Inc. has a quarterly dividend of $1.03 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENZ Therapeutics, Inc. pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LENZ or LIMN?
LENZ Therapeutics, Inc. quarterly revenues are $12.5M, which are larger than Liminatus Pharma quarterly revenues of --. LENZ Therapeutics, Inc.'s net income of -$16.7M is higher than Liminatus Pharma's net income of --. Notably, LENZ Therapeutics, Inc.'s price-to-earnings ratio is -- while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENZ Therapeutics, Inc. is 26.94x versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LENZLENZ Therapeutics, Inc.26.94x -- $12.5M -$16.7M LIMNLiminatus Pharma-- -- -- --
-
Which has Higher Returns LENZ or MAZE?
Maze Therapeutics, Inc. has a net margin of -133.6% compared to LENZ Therapeutics, Inc.'s net margin of --. LENZ Therapeutics, Inc.'s return on equity of -29.1% beat Maze Therapeutics, Inc.'s return on equity of -35.16%.
Company Gross Margin Earnings Per Share Invested Capital LENZLENZ Therapeutics, Inc.99% -$0.59 $194.9M MAZEMaze Therapeutics, Inc.-- -$0.63 $403.6M -
What do Analysts Say About LENZ or MAZE?
LENZ Therapeutics, Inc. has a consensus price target of $53.71, signalling upside risk potential of 218.02%. On the other hand Maze Therapeutics, Inc. has an analysts' consensus of $46.56 which suggests that it could grow by 10.06%. Given that LENZ Therapeutics, Inc. has higher upside potential than Maze Therapeutics, Inc., analysts believe LENZ Therapeutics, Inc. is more attractive than Maze Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LENZLENZ Therapeutics, Inc.6 0 0 MAZEMaze Therapeutics, Inc.9 0 0 -
Is LENZ or MAZE More Risky?
LENZ Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Maze Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LENZ or MAZE?
LENZ Therapeutics, Inc. has a quarterly dividend of $1.03 per share corresponding to a yield of 0%. Maze Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENZ Therapeutics, Inc. pays -- of its earnings as a dividend. Maze Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LENZ or MAZE?
LENZ Therapeutics, Inc. quarterly revenues are $12.5M, which are larger than Maze Therapeutics, Inc. quarterly revenues of --. LENZ Therapeutics, Inc.'s net income of -$16.7M is higher than Maze Therapeutics, Inc.'s net income of -$30.1M. Notably, LENZ Therapeutics, Inc.'s price-to-earnings ratio is -- while Maze Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENZ Therapeutics, Inc. is 26.94x versus 501.13x for Maze Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LENZLENZ Therapeutics, Inc.26.94x -- $12.5M -$16.7M MAZEMaze Therapeutics, Inc.501.13x -- -- -$30.1M
-
Which has Higher Returns LENZ or ORKA?
Oruka Therapeutics, Inc. has a net margin of -133.6% compared to LENZ Therapeutics, Inc.'s net margin of --. LENZ Therapeutics, Inc.'s return on equity of -29.1% beat Oruka Therapeutics, Inc.'s return on equity of -25.76%.
Company Gross Margin Earnings Per Share Invested Capital LENZLENZ Therapeutics, Inc.99% -$0.59 $194.9M ORKAOruka Therapeutics, Inc.-- -$0.69 $488.7M -
What do Analysts Say About LENZ or ORKA?
LENZ Therapeutics, Inc. has a consensus price target of $53.71, signalling upside risk potential of 218.02%. On the other hand Oruka Therapeutics, Inc. has an analysts' consensus of $49.45 which suggests that it could grow by 55.96%. Given that LENZ Therapeutics, Inc. has higher upside potential than Oruka Therapeutics, Inc., analysts believe LENZ Therapeutics, Inc. is more attractive than Oruka Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LENZLENZ Therapeutics, Inc.6 0 0 ORKAOruka Therapeutics, Inc.10 0 0 -
Is LENZ or ORKA More Risky?
LENZ Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oruka Therapeutics, Inc. has a beta of -0.409, suggesting its less volatile than the S&P 500 by 140.861%.
-
Which is a Better Dividend Stock LENZ or ORKA?
LENZ Therapeutics, Inc. has a quarterly dividend of $1.03 per share corresponding to a yield of 0%. Oruka Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. LENZ Therapeutics, Inc. pays -- of its earnings as a dividend. Oruka Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LENZ or ORKA?
LENZ Therapeutics, Inc. quarterly revenues are $12.5M, which are larger than Oruka Therapeutics, Inc. quarterly revenues of --. LENZ Therapeutics, Inc.'s net income of -$16.7M is higher than Oruka Therapeutics, Inc.'s net income of -$30.3M. Notably, LENZ Therapeutics, Inc.'s price-to-earnings ratio is -- while Oruka Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENZ Therapeutics, Inc. is 26.94x versus -- for Oruka Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LENZLENZ Therapeutics, Inc.26.94x -- $12.5M -$16.7M ORKAOruka Therapeutics, Inc.-- -- -- -$30.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
